Multi-biomarker test for the management of acute cardiac transplant rejection – Year two

The high incidence of acute organ rejection following heart transplantation poses major problems for patients, clinicians, and the healthcare system. A major clinical challenge in this regard arises from the difficulty of accurately and efficiently diagnosing when organ rejection occurs. In Canada, the current approach to diagnosing acute rejection requires taking small pieces of the endomyocardium (EMB), which is a highly invasive and costly procedure. An alternative approach, currently not available in Canada, is to use a blood-based biomarker test called AlloMap; however, this test is ineffective during the period immediately after a heart transplant, when most rejection events occur. TO BE CONT’D

Faculty Supervisor:

Robert McMaster

Student:

Partner:

PROOF Centre of Excellence

Discipline:

Life Sciences

Sector:

Biotechnology

University:

The University of British Columbia

Program: